Skip to main content

Table 2 Use of oral antidiabetic agents in the study subjects stratified by hypoglycemic event

From: Impact of sitagliptin combination therapy and hypoglycemia in Japanese patients with type 2 diabetes: a multi-center retrospective observational cohort study

Drugs

Overall population

Non-hypoglycemia

Hypoglycemia

P-value*

N (%)

N (%)

N (%)

SU

1468 (50.4)

1428 (49.8)

40 (87.0)

< 0.0001

TZD

662 (22.7)

646 (22.5)

16 (34.8)

0.0490

Glinide

59 (2.0)

59 (2.1)

0 (0.0)

 

AGI

393 (13.5)

378 (13.2)

15 (32.6)

0.0001

Biguanide

1152 (39.5)

1125 (39.2)

27 (58.7)

0.0074

β-blocker

318 (13.6)

307 (13.4)

11 (27.5)

0.0098

Diuretic

226 (9.7)

222 (9.7)

4 (10.0)

0.9440

ACE/ARB

1384 (59.3)

1362 (59.3)

22 (55.0)

0.5814

CCB

1096 (46.9)

1079 (47.0)

17 (42.5)

0.5723

  1. SU Sulfonylurea, TZD Thiazolidinedione, AGI Alpha-glucosidase inhibitors, ACE-I Angiotensin-converting enzyme inhibitors, ARB Angiotensin II receptor blocker, CCB Calcium channel blocker
  2. *Chi-squared tests were used in the analyses of categorical variables